Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; Issues relating to privacy and securing the data of and personal information of consumers General education on policies effecting development of pharmaceuticals, FDA approval and reimbursement.
Source-reported fields
Filing overview
- Type
- 1st Quarter - Termination
- Posted
- Apr 24, 2026
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- RIVENDELL GROUP LLP
- Client
- GENENTECH
- Filing UUID
- 2f23ab99-cbc6-45ab-8ebe-0be9c9e02bae
- Termination date
- Feb 28, 2026
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing. Issues related to the 340B Drug Discount Program. Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease;
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.